Premature Ejaculation - Pipeline Review, H2 2015

Description: Premature Ejaculation - Pipeline Review, H2 2015

Summary


This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Ejaculation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Premature Ejaculation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Premature Ejaculation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Premature Ejaculation Overview
Therapeutics Development
Pipeline Products for Premature Ejaculation - Overview
Premature Ejaculation - Therapeutics under Development by Companies
Premature Ejaculation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Premature Ejaculation - Products under Development by Companies
Premature Ejaculation - Companies Involved in Therapeutics Development
Allergan Plc
NeuroHealing Pharmaceuticals Inc.
Plethora Solutions Holdings Plc
SK Chemicals Co., Ltd.
Premature Ejaculation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles (lidocaine + prilocaine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(tramadol hydrochloride + PDE-5 Inhibitor) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IX-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE-405 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tramadol hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premature Ejaculation - Recent Pipeline Updates
Premature Ejaculation - Dormant Projects
Premature Ejaculation - Discontinued Products
Premature Ejaculation - Product Development Milestones
Featured News & Press Releases
Jan 08, 2015: Vyrix Pharmaceuticals to Present at Biotech Showcase 2015
Nov 11, 2014: Plethora Solutions Provides Company Update

Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU

Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment

Mar 11, 2014: Plethora Solutions Provides Company update

Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation

Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation

Jul 01, 2013: AGM Statement & PSD502 Regulatory Update

Jun 03, 2013: Ampio Pharma Provides Update On Sexual Dysfunction Portfolio

Mar 11, 2013: Ampio Receives FDA Acceptance Of Patient Outcome For Premature Ejaculation Questionnaire Paving Way For US Pivotal Trial On Zertane

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Premature Ejaculation, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Premature Ejaculation - Pipeline by Allergan Plc, H2 2015

Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc., H2 2015

Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H2 2015

Premature Ejaculation - Pipeline by SK Chemicals Co., Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Premature Ejaculation Therapeutics - Recent Pipeline Updates, H2 2015
Premature Ejaculation - Dormant Projects, H2 2015
Premature Ejaculation - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Premature Ejaculation, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3517301/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Premature Ejaculation - Pipeline Review, H2 2015
Web Address: http://www.researchandmarkets.com/reports/3517301/
Office Code: SCD2UV5K

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: __________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World